Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal imbalance, today announced a collaboration with Ciitizen, a Palo Alto based healthcare technology company that helps patients get full control of their medical records so they can find better treatment options, participate in research and find clinical trials. Praxis will utilize the Ciitizen platform to provide deeper insights across disease populations through the analysis of real-world data, initially to inform the development of PRAX-222 and PRAX-562 in SCN2A developmental and epileptic encephalopathy (SCN2A-DEE).
top of page
Search
Recent Posts
See AllBy: Steven Loeb Venture capital used to be a cottage industry, with very few investing in tomorrow's products and services. Oh, how times have changed! While there are more startups than ever, there's
Matterworks, Inc., developers of the world's most powerful metabolomics platform, which accelerates the discovery, development, and manufacturing of biologics and gene therapies, today announces updat
Luna, the leading provider of in-home physical therapy, has teamed up with UCI Health, to expand access to patient care by providing in-home physical therapy across Orange County, California. With a f
bottom of page